Celltrion has begun global Phase III trials on its ‘inhaled antibody cocktail therapy’ that is in development to respond to major variants of the COVID-19 virus, such as the Omicron variant.

According to the clinical trial registry ClinicalTrials.gov operated by the US National Institutes of Health (NIH), Celltrion newly registered a clinical trial protocol on initiating a Global Phase III trial for its ‘inhaled antibody cocktail therapy’ on the website on the 4th.

The trial will assess the therapeutic efficacy of the combination of ‘CT-P63’ and ‘CT-P66’ in an inhaled form to patients that were infected with mild-to-moderate COVID-19.

After enrolling patients who